Gregory M. Weinhoff - Feb 1, 2024 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Financial Officer
Signature
/s/ Gregory M. Weinhoff
Stock symbol
CNTA
Transactions as of
Feb 1, 2024
Transactions value $
-$94,136
Form type
4
Date filed
2/2/2024, 05:08 PM
Previous filing
Jan 2, 2024
Next filing
Apr 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Award $0 +31.3K +12.15% $0.00 288K Feb 1, 2024 Direct F1, F2
transaction CNTA Ordinary Shares Tax liability -$94.1K -11.5K -3.99% $8.19 277K Feb 1, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTA Share Option (right to buy) Award $0 +125K $0.00 125K Feb 1, 2024 Ordinary Shares 125K $8.01 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 1, 2025.
F3 Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
F4 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2024.